Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang Ki MinAsher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae Cheol Jo, Ho Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki Deangelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria Victoria Mateos

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk'. Together they form a unique fingerprint.

Medicine & Life Sciences